Results 231 to 240 of about 102,448 (310)

Protein Priming Followed by a Replication-Competent VSV-GP Vector Boost Induces Sustained Immune Control in Therapeutic Hepatitis B Vaccination. [PDF]

Vaccines (Basel)
Su J, Kosinska AD, Miko S, Ates Öz E, Laer DV, Kimpel J, Protzer U.   +6 more
europepmc   +1 more source

Therapeutic potential of natural products in cancer immunotherapy: Advances and challenges

British Journal of Pharmacology, EarlyView.
This review systematically outlines the mechanisms underlying tumour immunotherapy resistance and elucidates the role of natural products in enhancing therapeutic efficacy as immunomodulatory adjuvants. Abstract Immunotherapy has emerged as a clinically pivotal approach in cancer treatment, but its application remains limited to a small subset of ...
Rao Hu, Kaibin Dai, Zhensheng Lin, Mingfang Ye, Minfeng Chen, Xiaobo Li, Dongmei Zhang   +6 more
wiley   +1 more source

Precore/core mutation relatedness to viral reactivation in patients undergoing targeted therapy for hepatitis B virus-related hepatocellular carcinoma. [PDF]

World J Biol Chem
Abdulrahman MS, Aboelmagd O, Zhang Y, Zaky S, Johar D.   +4 more
europepmc   +1 more source

Targeting protein–protein interactions with reversible covalent modalities: Non‐cysteine chemistries

British Journal of Pharmacology, EarlyView.
Abstract Protein–protein interactions (PPIs) are central to diverse cellular functions, and represent a rapidly expanding class of therapeutic targets. Advancements in covalent drug design have enabled small‐molecule drugs to overcome challenges associated with engaging these targets, such as limited durations of action and difficult‐to‐drug (expansive,
Ruchira Basu, Steven Fletcher
wiley   +1 more source

Development of a Norway rat hepacivirus reporter for high-throughput quantification of neutralizing antibodies. [PDF]

J Virol
Kennedy MJ, Wolfisberg R, Lundsgaard EA, Thorselius CE, Collignon L, Nielsen L, Holmbeck K, Bukh J, Scheel TKH.   +8 more
europepmc   +1 more source

Cardiovascular toxicity from immune checkpoint inhibitor therapy: an inflammatory continuum

British Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitor (ICI) therapy has markedly improved outcomes in advanced malignancies but has also revealed a distinct spectrum of cardiovascular immune‐related adverse events. Myocarditis represents the most severe manifestation, while non‐inflammatory left ventricular dysfunction and vascular inflammation have emerged as additional ...
Fabrice Reyes, Florian Buehning, Tobias Lerchner, Julia Vogel, Raluca I. Mincu, Matthias Totzeck, Tienush Rassaf, Lars Michel   +7 more
wiley   +1 more source

Identification and P1 genetic evolutionary analysis of duck hepatitis a virus type 3 in selected areas of Jiangsu, China in 2024. [PDF]

Poult Sci
Yu J, Zhang T, Guo Z, Liu Y, Yuan M, Yang Z, Wang X, Song X, Jiang S, Wei L.   +9 more
europepmc   +1 more source

Padronização de métodos moleculares para a detecção do vírus da hepatite A em ostras Crassostrea gigas experimentalmente inoculadas [PDF]

, 2001
Coelho, Christiane
core  

Oncolytic Vaccinia Virus‐HSP70‐shRNA Amplifies Viral Replication, ROS/Autophagy, and Immunity to Fight Colorectal Cancer

Cancer Science, EarlyView.
OncoVV‑shHSP70, a vaccinia virus silencing HSP70, demonstrated potent antitumor efficacy in colorectal cancer cell lines, as well as in syngeneic, xenograft, and humanized mouse models. In cell lines, oncoVV‑shHSP70 promoted viral oncolysis and cytokine production through a self‑reinforcing cycle of ROS‑autophagy. In both CT26 and SW620‑humanized mouse
Rentao Yuan, Ruikang Liu, Fangying Shao, Zheqi Cai, Yingfei Fang, Kan Chen, Yanrong Zhou, Ting Ye, Gongchu Li   +8 more
wiley   +1 more source

Neutrophil extracellular traps: A central player in liver diseases. [PDF]

Hepatol Commun
Wang H, Tsung A, Zhang H.
europepmc   +1 more source